almitrine almitrine almitrine (marketed as duxil by servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the atc. it enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. the drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. it may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. a significant literature exists for this compound, including over 60 papers that medline labels as reviews. almitrineclinical dataahfs/drugs.cominternational drug namesatc coder07ab07 (who) identifiers iupac name 6-piperazin-1-yl]-n,n'-diprop-2-enyl-1,3,5-triazine-2,4-diamine cas number27469-53-0 ypubchem cid33887drugbankdb01430 ychemspider31235 yunii9a1222nbg4keggd07126 ychebichebi:53778 ychemblchembl1183717 ncomptox dashboard (epa)dtxsid4057899 echa infocard100.044.054 chemical and physical dataformulac26h29f2n7molar mass477.564 g·mol−13d model (jsmol)interactive imagemelting point181 °c (358 °f) smiles fc1ccc(cc1)c(c2ccc(f)cc2)n4ccn(c3nc(nc(n3)nc\c=c)nc\c=c)cc4 inchi inchi=1s/c26h29f2n7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23h,1-2,13-18h2,(h2,29,30,31,32,33) ykey:obdovfrmeyhsqb-uhfffaoysa-n y ny (what is this?) (verify) the clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by allain and bentué-ferrer. they summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. this paper further claims that the dosage and tolerance of the compound have been confirmed in a french multi-center study of 5,361 outpatients. under the brand names albasine, aruxil, and truxil, almitrine-raubasine has been marketed for rehabilitation after stroke, age related neurological disorders, visual disorders related to circulation, and tinnitus in bangladesh. synthesis patents: the reaction between 1-piperazine (1) and cyanuric chloride (2) gives 2-piperazin-1-yl]-4,6-dichloro-1,3,5-triazine, cid:134990507 (3). reaction with allylamine (4) completes the synthesis of almitrine (5).